Cytokinetics Expands MYQORZO Label with Phase 3 Data Showing Superiority Over Beta-Blockers
Event summary
- FDA approved supplemental New Drug Application for MYQORZO (aficamten) on November 16, 2026, expanding its label to include Phase 3 MAPLE-HCM trial data.
- MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden, and cardiac biomarkers compared to metoprolol in the MAPLE-HCM trial.
- MYQORZO is the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker in its U.S. label.
- The drug is subject to a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of heart failure.
The big picture
Cytokinetics' expanded label for MYQORZO positions the drug as a potential new standard of care for oHCM, challenging the decades-long dominance of beta-blockers. The strategic shift towards mechanism-specific therapies for hypertrophic cardiomyopathy reflects broader industry trends in precision cardiovascular medicine. The company's ability to leverage this approval to expand into other cardiac muscle dysfunction indications will be critical for long-term growth.
What we're watching
- Market Adoption
- How quickly cardiologists will adopt MYQORZO as a first-line treatment for obstructive hypertrophic cardiomyopathy (oHCM) over established beta-blockers.
- Regulatory Scrutiny
- Whether the FDA's REMS program will impact MYQORZO's market penetration due to the stringent monitoring requirements.
- Pipeline Progress
- The pace at which Cytokinetics advances aficamten for non-obstructive hypertrophic cardiomyopathy (nHCM) and other indications.
